Published in Am J Pathol on October 30, 2008
Inflammation, a link between obesity and cardiovascular disease. Mediators Inflamm (2010) 1.80
Serum amyloid A as a marker of persistent inflammation and an indicator of cardiovascular and renal involvement in patients with rheumatoid arthritis. Mediators Inflamm (2014) 1.52
Serum amyloid A directly accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Mol Med (2011) 1.13
A murine model of obesity with accelerated atherosclerosis. Obesity (Silver Spring) (2009) 1.10
Deficiency of endogenous acute phase serum amyloid A does not affect atherosclerotic lesions in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol (2013) 0.91
A brief elevation of serum amyloid A is sufficient to increase atherosclerosis. J Lipid Res (2014) 0.88
Proteomic analysis of plasma-purified VLDL, LDL, and HDL fractions from atherosclerotic patients undergoing carotid endarterectomy: identification of serum amyloid A as a potential marker. Oxid Med Cell Longev (2013) 0.85
Establishment of a transgenic mouse model specifically expressing human serum amyloid A in adipose tissue. PLoS One (2011) 0.84
Increased atherosclerosis in mice with increased vascular biglycan content. Atherosclerosis (2014) 0.83
Serum amyloid A is found on ApoB-containing lipoproteins in obese humans with diabetes. Obesity (Silver Spring) (2013) 0.82
Plasma proteomics of differential outcome to long-term therapy in children with idiopathic pulmonary arterial hypertension. Proteomics Clin Appl (2012) 0.81
Serum Amyloid A Facilitates Early Lesion Development in Ldlr-/- Mice. J Am Heart Assoc (2015) 0.79
Adipose tissue-derived human serum amyloid a does not affect atherosclerotic lesion area in hSAA1+/-/ApoE-/- mice. PLoS One (2014) 0.79
Localized thymic amyloidosis presenting with myasthenia gravis: case report. J Korean Med Sci (2013) 0.78
Serum amyloid A is a marker for pulmonary involvement in systemic sclerosis. PLoS One (2015) 0.78
Deficiency of Endogenous Acute-Phase Serum Amyloid A Protects apoE-/- Mice From Angiotensin II-Induced Abdominal Aortic Aneurysm Formation. Arterioscler Thromb Vasc Biol (2015) 0.77
Impact of individual acute phase serum amyloid A isoforms on HDL metabolism in mice. J Lipid Res (2016) 0.76
The correlation between the cardio-ankle vascular index (CAVI) and serum amyloid A in asymptomatic Japanese subjects. Heart Vessels (2011) 0.76
Serum amyloid A and pairing formyl peptide receptor 2 are expressed in corneas and involved in inflammation-mediated neovascularization. Int J Ophthalmol (2014) 0.76
C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med (2000) 18.04
Elevated C-reactive protein levels in overweight and obese adults. JAMA (1999) 9.94
Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem (1999) 4.94
Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation (2007) 4.62
The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol (1995) 4.60
Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature (2002) 3.80
Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res (2001) 3.07
Amyloid protein SAA is associated with high density lipoprotein from human serum. Proc Natl Acad Sci U S A (1977) 3.04
Monoclonal antibodies recognizing transforming growth factor-beta. Bioactivity neutralization and transforming growth factor beta 2 affinity purification. J Immunol (1989) 3.00
Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care (2000) 2.63
Early human atherosclerosis: accumulation of lipid and proteoglycans in intimal thickenings followed by macrophage infiltration. Arterioscler Thromb Vasc Biol (2007) 2.58
Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol (2001) 2.44
Pathology of atheromatous lesions in inbred and genetically engineered mice. Genetic determination of arterial calcification. Arterioscler Thromb (1994) 2.31
Characteristics of intact and ruptured atherosclerotic plaques in brachiocephalic arteries of apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol (2002) 2.27
Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition. J Biol Chem (1986) 2.25
Quantification of atherosclerosis in mice. Methods Mol Biol (2003) 2.20
The implication of obesity and central fat on markers of chronic inflammation: The ATTICA study. Atherosclerosis (2005) 2.18
Dietary cholesterol worsens adipose tissue macrophage accumulation and atherosclerosis in obese LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol (2008) 1.97
Coronary C-reactive protein distribution: its relation to development of atherosclerosis. Atherosclerosis (1999) 1.96
Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits. J Lipid Res (2007) 1.96
Serum amyloid A induces IL-8 secretion through a G protein-coupled receptor, FPRL1/LXA4R. Blood (2002) 1.92
Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression. Arterioscler Thromb Vasc Biol (2002) 1.69
Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: implications for serum amyloid A function. Proc Natl Acad Sci U S A (1994) 1.63
The response-to-retention hypothesis of atherogenesis reinforced. Curr Opin Lipidol (1998) 1.62
Increase in serum amyloid a evoked by dietary cholesterol is associated with increased atherosclerosis in mice. Circulation (2004) 1.61
Effects of platelet-derived growth factor and transforming growth factor-beta 1 on the synthesis of a large versican-like chondroitin sulfate proteoglycan by arterial smooth muscle cells. J Biol Chem (1991) 1.55
Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation (2002) 1.54
Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: colocalization of biglycan with apolipoproteins. Circulation (1998) 1.52
Serum amyloid A and lipoprotein retention in murine models of atherosclerosis. Arterioscler Thromb Vasc Biol (2005) 1.43
Serum amyloid A stimulates matrix-metalloproteinase-9 upregulation via formyl peptide receptor like-1-mediated signaling in human monocytic cells. Biochem Biophys Res Commun (2005) 1.40
Accumulation of biglycan and perlecan, but not versican, in lesions of murine models of atherosclerosis. Arterioscler Thromb Vasc Biol (2002) 1.30
Local generation of C-reactive protein in diseased coronary artery venous bypass grafts and normal vascular tissue. Circulation (2003) 1.27
Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE-/- mice. Atherosclerosis (2007) 1.24
Platelet-derived growth factor and transforming growth factor-beta 1 differentially affect the synthesis of biglycan and decorin by monkey arterial smooth muscle cells. Arterioscler Thromb (1993) 1.18
Cholesterol feeding increases C-reactive protein and serum amyloid A levels in lean insulin-sensitive subjects. Circulation (2005) 1.16
Heparan sulfate in perlecan promotes mouse atherosclerosis: roles in lipid permeability, lipid retention, and smooth muscle cell proliferation. Circ Res (2008) 1.15
The association of c-reactive protein, serum amyloid a and fibrinogen with prevalent coronary heart disease--baseline findings of the PAIS project. Atherosclerosis (2001) 1.12
Proteoglycans synthesized by arterial smooth muscle cells in the presence of transforming growth factor-beta1 exhibit increased binding to LDLs. Arterioscler Thromb Vasc Biol (2002) 1.11
Retention of low-density lipoprotein in atherosclerotic lesions of the mouse: evidence for a role of lipoprotein lipase. Circ Res (2007) 1.11
Angiotensin II increases vascular proteoglycan content preceding and contributing to atherosclerosis development. J Lipid Res (2007) 1.08
Smad4/DPC4-dependent regulation of biglycan gene expression by transforming growth factor-beta in pancreatic tumor cells. J Biol Chem (2002) 1.02
Oxidized low density lipoproteins regulate synthesis of monkey aortic smooth muscle cell proteoglycans that have enhanced native low density lipoprotein binding properties. J Biol Chem (2000) 1.00
Characterization of amyloid related protein SAA complexed with serum lipoproteins (apoSAA). Clin Exp Immunol (1982) 0.99
Influence of apoA-I and apoE on the formation of serum amyloid A-containing lipoproteins in vivo and in vitro. J Lipid Res (2003) 0.99
Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women. Diabetologia (2003) 0.97
A serum amyloid A and LDL complex as a new prognostic marker in stable coronary artery disease. Atherosclerosis (2004) 0.96
Atherosclerosis in perlecan heterozygous mice. J Lipid Res (2004) 0.96
Expression of serum amyloid A protein in the absence of the acute phase response does not reduce HDL cholesterol or apoA-I levels in human apoA-I transgenic mice. J Lipid Res (1999) 0.95
Smooth muscle cell biglycan overexpression results in increased lipoprotein retention on extracellular matrix: implications for the retention of lipoproteins in atherosclerosis. Atherosclerosis (2004) 0.95
Decorin overexpression reduces atherosclerosis development in apolipoprotein E-deficient mice. Atherosclerosis (2005) 0.92
Regulation of biglycan gene expression by transforming growth factor-beta requires MKK6-p38 mitogen-activated protein Kinase signaling downstream of Smad signaling. J Biol Chem (2003) 0.90
Both acute phase and constitutive serum amyloid A are present in atherosclerotic lesions. Pathol Int (1996) 0.85
Arterial smooth muscle cell proteoglycans synthesized in the presence of glucosamine demonstrate reduced binding to LDL. J Lipid Res (2002) 0.84
Altered proteoglycan synthesis via the false acceptor pathway can be dissociated from beta-D-xyloside inhibition of proliferation. Arch Biochem Biophys (1992) 0.83
Regulation of vascular proteoglycan synthesis by metabolic factors associated with diabetes. J Investig Med (2007) 0.82
Proteoglycans in macrophages: characterization and possible role in the cellular uptake of lipoproteins. Biochem J (1998) 0.81
Thiazolidinediones reduce the LDL binding affinity of non-human primate vascular cell proteoglycans. Diabetologia (2004) 0.81
Human monocyte-derived macrophages secrete two forms of proteoglycan-macrophage colony-stimulating factor that differ in their ability to bind low density lipoproteins. J Biol Chem (1998) 0.80
Acute-phase, but not constitutive serum amyloid A (SAA) is chemotactic for cultured human aortic smooth muscle cells. Amyloid (2002) 0.80
Lipoprotein-matrix interactions in macrovascular disease in diabetes. Front Biosci (2004) 0.79
Measurements of proteoglycan-lipoprotein interaction by gel mobility shift assay. Methods Mol Biol (1998) 0.79
Transforming growth factor-beta-1 latency-associated peptide and soluble betaglycan prevent a glucose-induced increase in fibronectin production in cultured human mesangial cells. Nephron (2002) 0.78
Group v secretory phospholipase A2 promotes atherosclerosis: evidence from genetically altered mice. Arterioscler Thromb Vasc Biol (2007) 1.89
High-density lipoprotein suppresses the type I interferon response, a family of potent antiviral immunoregulators, in macrophages challenged with lipopolysaccharide. Circulation (2010) 1.80
Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. J Clin Invest (2004) 1.73
Mouse models of the metabolic syndrome. Dis Model Mech (2010) 1.55
Serum amyloid A promotes cholesterol efflux mediated by scavenger receptor B-I. J Biol Chem (2005) 1.55
SR-BI protects against endotoxemia in mice through its roles in glucocorticoid production and hepatic clearance. J Clin Invest (2008) 1.48
Group X secretory phospholipase A(2) augments angiotensin II-induced inflammatory responses and abdominal aortic aneurysm formation in apoE-deficient mice. Atherosclerosis (2010) 1.48
HDL cholesterol transport during inflammation. Curr Opin Lipidol (2007) 1.45
HDL remodeling during the acute phase response. Arterioscler Thromb Vasc Biol (2008) 1.40
Serum amyloid A is a ligand for scavenger receptor class B type I and inhibits high density lipoprotein binding and selective lipid uptake. J Biol Chem (2004) 1.32
Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges. Circulation (2013) 1.23
High density lipoprotein uptake by scavenger receptor SR-BII. J Biol Chem (2004) 1.21
Low-density lipoprotein from apolipoprotein E-deficient mice induces macrophage lipid accumulation in a CD36 and scavenger receptor class A-dependent manner. Arterioscler Thromb Vasc Biol (2004) 1.20
Group V sPLA2 hydrolysis of low-density lipoprotein results in spontaneous particle aggregation and promotes macrophage foam cell formation. Arterioscler Thromb Vasc Biol (2004) 1.18
High density lipoprotein endocytosis by scavenger receptor SR-BII is clathrin-dependent and requires a carboxyl-terminal dileucine motif. J Biol Chem (2005) 1.17
Biology of secretory phospholipase A2. Cardiovasc Drugs Ther (2008) 1.17
Distinct mechanisms for OxLDL uptake and cellular trafficking by class B scavenger receptors CD36 and SR-BI. J Lipid Res (2007) 1.15
Intestinal epithelial serum amyloid A modulates bacterial growth in vitro and pro-inflammatory responses in mouse experimental colitis. BMC Gastroenterol (2010) 1.13
Aldosterone does not mediate angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. Br J Pharmacol (2005) 1.10
A murine model of obesity with accelerated atherosclerosis. Obesity (Silver Spring) (2009) 1.10
Serum amyloid A in atherosclerosis. Curr Opin Lipidol (2011) 1.09
Angiotensin II increases vascular proteoglycan content preceding and contributing to atherosclerosis development. J Lipid Res (2007) 1.08
Group V secretory phospholipase A2-modified low density lipoprotein promotes foam cell formation by a SR-A- and CD36-independent process that involves cellular proteoglycans. J Biol Chem (2005) 1.06
Clinical efficacy and patient satisfaction with U-500 insulin use. Diabetes Res Clin Pract (2010) 1.04
Inflammation-dependent cerebral deposition of serum amyloid a protein in a mouse model of amyloidosis. J Neurosci (2002) 1.03
Thiol oxidative stress induced by metabolic disorders amplifies macrophage chemotactic responses and accelerates atherogenesis and kidney injury in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol (2009) 1.02
Adenovirus-mediated hepatic overexpression of scavenger receptor class B type I accelerates chylomicron metabolism in C57BL/6J mice. J Lipid Res (2005) 1.01
Syndecan-4 mediates macrophage uptake of group V secretory phospholipase A2-modified LDL. J Lipid Res (2008) 0.99
Transforming growth factor-β regulation of proteoglycan synthesis in vascular smooth muscle: contribution to lipid binding and accelerated atherosclerosis in diabetes. J Diabetes (2010) 0.99
Influence of apoA-I and apoE on the formation of serum amyloid A-containing lipoproteins in vivo and in vitro. J Lipid Res (2003) 0.99
Scavenger receptor SR-BI in macrophage lipid metabolism. Atherosclerosis (2011) 0.97
Macrophage-expressed group IIA secretory phospholipase A2 increases atherosclerotic lesion formation in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol (2003) 0.97
Nascent HDL formation in hepatocytes and role of ABCA1, ABCG1, and SR-BI. J Lipid Res (2011) 0.97
Impact of serum amyloid A on high density lipoprotein composition and levels. J Lipid Res (2010) 0.95
Köbberling type of familial partial lipodystrophy: an underrecognized syndrome. Diabetes Care (2003) 0.95
SAA does not induce cytokine production in physiological conditions. Cytokine (2012) 0.91
The capacity of group V sPLA2 to increase atherogenicity of ApoE-/- and LDLR-/- mouse LDL in vitro predicts its atherogenic role in vivo. Arterioscler Thromb Vasc Biol (2009) 0.91
Deficiency of endogenous acute phase serum amyloid A does not affect atherosclerotic lesions in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol (2013) 0.91
Thematic review series: The immune system and atherogenesis. Cytokine regulation of macrophage functions in atherogenesis. J Lipid Res (2005) 0.90
Extreme insulin resistance: indications and approaches to the use of U-500 insulin in type 2 diabetes mellitus. Curr Diab Rep (2011) 0.90
Group X secretory phospholipase A2 regulates the expression of steroidogenic acute regulatory protein (StAR) in mouse adrenal glands. J Biol Chem (2010) 0.89
Group X secretory phospholipase A2 negatively regulates adipogenesis in murine models. FASEB J (2010) 0.89
Quantitative analysis of SR-BI-dependent HDL retroendocytosis in hepatocytes and fibroblasts. J Lipid Res (2006) 0.88
Renal accumulation of biglycan and lipid retention accelerates diabetic nephropathy. Am J Pathol (2011) 0.88
ATP binding cassette G1-dependent cholesterol efflux during inflammation. J Lipid Res (2010) 0.87
Differential effects of rosiglitazone and insulin glargine on inflammatory markers, glycemic control, and lipids in type 2 diabetes. Diabetes Res Clin Pract (2007) 0.87
Proteoglycan mediated lipoprotein retention: a mechanism of diabetic atherosclerosis. Rev Endocr Metab Disord (2008) 0.87
Overexpression of SR-BI by adenoviral vector promotes clearance of apoA-I, but not apoB, in human apoB transgenic mice. J Lipid Res (2002) 0.86
Nascent HDL formation by hepatocytes is reduced by the concerted action of serum amyloid A and endothelial lipase. J Lipid Res (2011) 0.86
ApoB-containing lipoproteins in apoE-deficient mice are not metabolized by the class B scavenger receptor BI. J Lipid Res (2003) 0.85
ApoA-II modulates the association of HDL with class B scavenger receptors SR-BI and CD36. J Lipid Res (2004) 0.85
The Impairment of Macrophage-to-Feces Reverse Cholesterol Transport during Inflammation Does Not Depend on Serum Amyloid A. J Lipids (2013) 0.85
Decreased body fat, elevated plasma transforming growth factor-β levels, and impaired BMP4-like signaling in biglycan-deficient mice. Connect Tissue Res (2012) 0.85
Group X secretory phospholipase A2 negatively regulates ABCA1 and ABCG1 expression and cholesterol efflux in macrophages. Arterioscler Thromb Vasc Biol (2010) 0.84
Getting to the core of atherosclerosis. Nat Med (2008) 0.84
Imatinib inhibits vascular smooth muscle proteoglycan synthesis and reduces LDL binding in vitro and aortic lipid deposition in vivo. J Cell Mol Med (2009) 0.84
The fate of HDL particles in vivo after SR-BI-mediated selective lipid uptake. J Lipid Res (2002) 0.83
Lack of a direct role for macrosialin in oxidized LDL metabolism. J Lipid Res (2003) 0.83
SR-BI selective lipid uptake: subsequent metabolism of acute phase HDL. Arterioscler Thromb Vasc Biol (2009) 0.83
Bioactive products generated by group V sPLA(2) hydrolysis of LDL activate macrophages to secrete pro-inflammatory cytokines. Cytokine (2010) 0.82
Serum amyloid A is found on ApoB-containing lipoproteins in obese humans with diabetes. Obesity (Silver Spring) (2013) 0.82
Prevention of TGFβ induction attenuates angII-stimulated vascular biglycan and atherosclerosis in Ldlr-/- mice. J Lipid Res (2013) 0.82
SR-BI-mediated selective lipid uptake segregates apoA-I and apoA-II catabolism. J Lipid Res (2005) 0.82
Managing highly insulin-resistant diabetes mellitus: weight loss approaches and medical management. Postgrad Med (2010) 0.82
Remodeling of HDL remnants generated by scavenger receptor class B type I. J Lipid Res (2004) 0.82
Regulation of vascular proteoglycan synthesis by metabolic factors associated with diabetes. J Investig Med (2007) 0.82
Endogenous androgen deficiency enhances diet-induced hypercholesterolemia and atherosclerosis in low-density lipoprotein receptor-deficient mice. Gend Med (2012) 0.81
Glucosamine inhibits the synthesis of glycosaminoglycan chains on vascular smooth muscle cell proteoglycans by depletion of ATP. Arch Physiol Biochem (2008) 0.81
Statin-exposed vascular smooth muscle cells secrete proteoglycans with decreased binding affinity for LDL. J Lipid Res (2003) 0.81
IL-5 links adaptive and natural immunity in reducing atherosclerotic disease. J Clin Invest (2004) 0.80
Durability of glycemic control using U-500 insulin. Diabetes Res Clin Pract (2011) 0.80
Group X secretory phospholipase A2 enhances TLR4 signaling in macrophages. J Immunol (2011) 0.79
Reversibility of renal injury with cholesterol lowering in hyperlipidemic diabetic mice. J Lipid Res (2010) 0.79
Glucosamine supplementation accelerates early but not late atherosclerosis in LDL receptor-deficient mice. J Nutr (2006) 0.78
Serum amyloid A impairs the antiinflammatory properties of HDL. J Clin Invest (2015) 0.78
Group V secretory phospholipase A2 enhances the progression of angiotensin II-induced abdominal aortic aneurysms but confers protection against angiotensin II-induced cardiac fibrosis in apoE-deficient mice. Am J Pathol (2012) 0.78
Inflammation and atherosclerosis: Group IIa and Group V sPLA2 are not redundant. Arterioscler Thromb Vasc Biol (2006) 0.77